Business · 1 sources covering this

Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar

The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

The HinduLean L·1h ago
Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
Read at The Hindu →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/7333ee564b34abc61e65144a9af779c02288b369"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar"></iframe>

Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar

How 1 sources are covering this

Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar

More from Business

How will the US-Venezuela oil deal work? Alejandro Betancourt, China and Trump’s 65 bn barrel bet | All you need to know

Microfinance recovery to help SFB gross NPAs decline in FY27: Crisil

Women's Asia Cup: Mandhana's ton powers India to 137-run win vs Hong Kong

Nick Kyrgios accepts one-month suspension following positive cocaine test

Reader

Trust & legal

Across the network